🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Amazing start of the day with Ngawai and Niccola, proving an introduction to how those with lived experience of the condition can shape research #heavyperiods #menstrualhealth

🚨New podcast episode out now and it's all about #MetaAnalysis! Peter Godolphin & @pgd81 discuss the new ‘within-trial framework for subgroup analysis', to work out which #ClinicalTrials participants benefit most from a treatment. 🎧Listen now: bit.ly/43boETF

'How can IPD improve precision medicine?' 'Can IPD improve evidence quality?' All your IPD-questions answered! Join our symposium NHMRC CTC with international IPD experts: Peter Godolphin Rui Wang Kylie Hunter Dr. Libesman Sign up here➡️bit.ly/4crhO0z

Looking for something to listen to over the bank holiday weekend?🎧 Then check out the latest episode of our Trial Talk podcast, where Peter Godolphin & @pgd81 explain how we work out which subgroups of trial participants benefit most from a treatment. bit.ly/43boETF

Join me for the 33rd Joint London School of Hygiene & Tropical Medicine - Royal Statistical Society Perspectives on Statistics in Medicine Annual Lecture (formerly Bradford Hill Memorial Lecture). 📅 26th June 2024 ⏲️ 1730-1830 (BST) 📍 John Snow Lecture Theatre, London School of Hygiene & Tropical Medicine WC1E 7HT Link to join online: lshtm.zoom.us/j/98398749667#…

Better late than never 😀 Finally met in-person with Lesley Stewart & Jayne Tierney, 3 years after our IPD meta-analysis book was published! We began in 2014, so a long journey, but rewarding to see the book (& ipdma.co.uk) now helping others on their IPDMA projects 🙏

Ever wonder if there is a difference in docetaxel vs. ARPI combination in de novo mHSPC? Would like to highlight our work using Veterans Affairs real-world data to answer a question since no trial exists In 1,222 vets, no difference in overall survival meetings.asco.org/abstracts-pres…

Presenting about Kylie Hunter 's brilliant IPDIntegrity tool shortly #WCRI2024 at the session with the intriguing name 'Oral presentations 17' - come listen if you would like to find out how to use raw data to uncover integrity issues

🧵 Excited to share our latest paper in JAMA Oncology! Omar El-Taji led this meta-analysis to explore 🫀cardiovascular (CV) risks associated with 💊 androgen receptor signalling inhibitors (ARSI) in advanced prostate cancer (PCa). GU Cancer Research group Division of Cancer Sciences #CardioOncology

Glad to get this important work out on the 🫀effects of ARSI treatment in PCa Have a read of Ashwin Sachdeva break down of the meta-analysis. JAMA Oncology GU Cancer Research group Salford Urology Article available 👇🏼 tinyurl.com/k6362xpn

Do you experience heavy menstrual bleeding? Do your heavy #periods affect your daily life?🩸 We want to know about your experiences. #TalkingPeriods Help us improve policies & guidelines around the treatment of heavy periods by completing this survey: forms.office.com/e/X5D5skjtcG

🆕25 at 25: We develop openly-available, user-friendly software packages to encourage researchers to implement our novel methods. Discover how our statistical software helps improve #ClinicalTrials & #MetaAnalysis globally. More details👉bit.ly/4cgwxKM #StatsTwitter

How to interpret rankings in NMA, e.g. iCOMP finding that waiting longer to clamp the cord has 91% probability of being the best treatment? In this new The Lancet correspondence we explain our approach, guided by Sofia Dias 😷, Richard Riley (R²) & others: thelancet.com/journals/lance…

PUBLISHED! The 30th Annual Prostate Cancer Foundation Scientific Retreat Report, which summarizes the cutting-edge research in #ProstateCancer & other fields presented at the 2023 Prostate Cancer Foundation Retreat. #PCFRetreat23 Howard Soule Andrea Miyahira onlinelibrary.wiley.com/doi/epdf/10.10…

A brilliant resource for statisticians & methodologists!

Table 22 YIA speed networking poetry competition 🗳️ vote with a like #pcfretreat24 PCF Science Prostate Cancer Foundation

Words have power: to empower, to teach, and to optimize, but also to scare, to confuse, and to withhold👉For our pts with #prostatecancer 👉Prostate Cancer Foundation roundtable team asks to avoid words like “castration,” & adapt the following👇UroToday.com European Urology Link👉 bit.ly/4f35h44

PROSTATE CANCER: 1/ STOPCAP Meta-Analysis: Who Benefits Most from ARPIs in mHSPC? OS benefit with ARPI + ADT (HR 0.69). Greater PFS benefit in younger, higher BMI, & low-volume disease. ARPI vs docetaxel doublets show similar efficacy in high-volume synchronous disease.

🚨STOPCAT meta-analyses of IPD assess ARPIs for mHSPC 🗣️David Fisher, MSc 🔑Takeaways 1️⃣All ARPIs benefit these pts 2️⃣Need to balance risk/benefits in older pts #GU25 ASCO PCF Science Prostate Cancer Foundation 🖊️Adam B. Weiner, MD

⚕️💡👥Calling all UCL staff & PhDs! Join our UCL Health of the Public The Bartlett School of Sustainable Construction UCL_EFID_Research Centre 12 & 19 June workshops exploring how STEMB, humanities & social science discipline researchers understand conceptions of #health to address critical #globalhealth challenges eventbrite.co.uk/e/health-beyon…